缩写名/全名 |
J DRUG TARGET
JOURNAL OF DRUG TARGETING |
||||||||||||||||
ISSN号 | 1061-186X | ||||||||||||||||
研究方向 | 医学-药学 | ||||||||||||||||
影响因子 | 2015:2.821, 2016:3.068, 2017:3.408, 2018:3.277, 2019:3.38, | ||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||
出版周期 | Bimonthly | ||||||||||||||||
年文章数 | 104 | ||||||||||||||||
出版年份 | 1993 | ||||||||||||||||
是否OA | No | ||||||||||||||||
审稿周期(仅供参考) | 平均2月 |
||||||||||||||||
录用比例 | 约75% | ||||||||||||||||
投稿链接 | https://mc.manuscriptcentral.com/gdrt | ||||||||||||||||
投稿官网 | http://www.tandfonline.com/toc/idrt20/current | ||||||||||||||||
h-index | 80 | ||||||||||||||||
CiteScore |
|
||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1061-186X%5BISSN%5D | ||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | NLRP3 inflammasome contributes to neurovascular unit damage in stroke. Author: Jing S1, Chi L1, He Z2, Gao Y1, Gao Y2, Huang Y1, Nan G1. Journal: J Drug Target. 2019 Jan 2:1-22. doi: 10.1080/1061186X.2018.1564925. [Epub ahead of print] PubMed DOI |
2. | ANGPTL3: a novel biomarker and promising therapeutic target. Author: Jiang S1,2, Qiu GH1,3, Zhu N4, Hu ZY5, Liao DF1,2, Qin L1,2. Journal: J Drug Target. 2019 Jan 7:1-9. doi: 10.1080/1061186X.2019.1566342. [Epub ahead of print] PubMed DOI |
3. | Construction of novel procoagulant protein targeting neuropilin-1 on tumour vasculature for tumour embolization therapy. Author: Zou M1, Samiullah M1, Xu P1, Wang S1, He J1, Wu T1, Luo F1, Yan J1. Journal: J Drug Target. 2019 Jan 21:1-11. doi: 10.1080/1061186X.2019.1566337. [Epub ahead of print] PubMed DOI |
4. | A mitochondrion-targeting tanshinone IIA derivative attenuates myocardial hypoxia reoxygenation injury through a SDH-dependent antioxidant mechanism. Author: Zhao YP1, Wang F1, Jiang W1, Liu J2, Liu BL1, Qi LW1, Zhou W1. Journal: J Drug Target. 2019 Jan 11:1-7. doi: 10.1080/1061186X.2019.1566338. [Epub ahead of print] PubMed DOI |
5. | Advances in curcumin-loaded nanopreparations: improving bioavailability and overcoming inherent drawbacks. Author: Zhang Y1, Rauf Khan A1, Fu M1, Zhai Y2, Ji J1, Bobrovskaya L3, Zhai G1. Journal: J Drug Target. 2019 Jan 23:1-32. doi: 10.1080/1061186X.2019.1572158. [Epub ahead of print] PubMed DOI |
6. | Mycobacterium tuberculosis metC (Rv3340) derived hydrogen sulphide conferring bacteria stress survival. Author: Nzungize L1, Ali MK1, Wang X1, Huang X1, Yang W1, Duan X1, Yan S1, Li C1, Abdalla AE1,2, Jeyakkumar P3, Xie J1. Journal: J Drug Target. 2019 Feb 7:1-13. doi: 10.1080/1061186X.2019.1579820. [Epub ahead of print] PubMed DOI |
7. | NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway. Author: Li B1, Gu W2, Zhu X3. Journal: J Drug Target. 2019 Feb 20:1-7. doi: 10.1080/1061186X.2019.1585437. [Epub ahead of print] PubMed DOI |
8. | A novel conjunction of folate-targeted carbon nanotubes containing protohemin and oridonin-liposome loaded microbubbles for cancer chemo-sonodynamic therapy. Author: Wang CJ1, Wang HZ2, Li W1. Journal: J Drug Target. 2019 Mar 6:1-20. doi: 10.1080/1061186X.2019.1591422. [Epub ahead of print] PubMed DOI |
9. | S3Ab, a novel antibody targeting B lymphocytes, is a potential therapeutic agent for B-lineage malignancies. Author: Li S1, Shen H2, Shu Q3. Journal: J Drug Target. 2019 Mar 11:1-8. doi: 10.1080/1061186X.2019.1584809. [Epub ahead of print] PubMed DOI |
10. | Penetration of different molecule sizes upon ultrasound combined with microbubbles in a superficial tumour model. Author: Wei Y1, Shang N1, Jin H2, He Y2, Pan Y2, Xiao N2, Wei J2, Xiao S2, Chen L2, Liu J2. Journal: J Drug Target. 2019 Mar 20:1-8. doi: 10.1080/1061186X.2019.1588279. [Epub ahead of print] PubMed DOI |
|
|